Technical Analysis for ANNX - Annexon, Inc.

Grade Last Price % Change Price Change
grade D 21.01 -3.76% -0.82
ANNX closed up 13.52 percent on Wednesday, August 5, 2020, on 1.32 times normal volume. The bulls were able to push the stock to a new 52-week high.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A N/A
Historical ANNX trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish -3.76%
New 52 Week High Strength -3.76%
Multiple of Ten Bullish Other -3.76%
NR7 Range Contraction 9.26%
Multiple of Ten Bearish Other 9.26%
Inside Day Range Contraction 9.26%
New 52 Week Closing High Bullish 5.84%
New 52 Week High Strength 5.84%
Multiple of Ten Bearish Other 5.84%
New 52 Week High Strength 14.12%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The company’s pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. The company’s first product candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. The company’s second product candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. Annexon is advancing its current programs while evaluating additional orphan and large market indications. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended patient tissue.
Medicine Biotechnology Biopharmaceutical Medical Specialties Clinical Medicine Immunology Immune System Antibody Autoimmunity Monoclonal Antibody Platform Technology Complement System

Is ANNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 22.3699
52 Week Low 15.33
Average Volume 221,182
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 0.00
Average True Range 0.00
ADX 0.0
+DI 0.00
-DI 0.00
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line 0.00
MACD Signal Line 0.00
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 26.87
Resistance 3 (R3) 26.49 24.43 26.03
Resistance 2 (R2) 24.43 23.15 24.62 25.75
Resistance 1 (R1) 23.13 22.35 23.78 23.51 25.47
Pivot Point 21.07 21.07 21.39 21.26 21.07
Support 1 (S1) 19.77 19.79 20.42 20.15 18.19
Support 2 (S2) 17.71 18.99 17.90 17.91
Support 3 (S3) 16.41 17.71 17.63
Support 4 (S4) 16.79